Advanced CSCC

Patient Characteristics

Approved as a first- or later-line therapy for a broad range
of patients with advanced CSCC1

Characteristics of patients with mCSCC or laCSCC who were not candidates for
curative surgery or curative radiation, and who enrolled in Study 15401

 
Combined advanced CSCC Groups 1, 2, & 3 (N=193)
mCSCC, n 115
laCSCC, n 78
Median age, years (range) 72 (38-96)
Male, % 83
White, % 97
ECOG PS, %
0 45
1 55

CSCC=cutaneous squamous cell carcinoma; ECOG=Eastern Cooperative Oncology Group; laCSCC=locally advanced CSCC;
mCSCC=metastatic CSCC; PD-L1=programmed death ligand 1; PS=performance status.

LIBTAYO was studied in a broad range
of patients with advanced CSCC1

66%

received LIBTAYO as a first-line
systemic therapy2

90%

received prior cancer-related surgery1

68%

received prior radiotherapy1

23%

with mCSCC had only nodal metastases1

77%

with mCSCC had distant metastases1

No PD-L1 testing is required before starting LIBTAYO in advanced CSCC1,3

LIBTAYO is approved for a wide variety of patients with advanced CSCC

Patients with mCSCC1
  • Nodal metastasis
  • Distant metastasis
Patients with laCSCC1
  • Patients with laCSCC who are not candidates for curative surgery or curative radiation
Situations when surgery may not be appropriate3,4*
Invasive disease
  • Locally invasive: Tumor
    extending into underlying
    tissue, cartilage, bone, or
    nerve
  • Nodal involvement due to
    direct invasion from
    overlying skin
  • Perineural involvement due
    to direct extension that is
    apparent on imaging
  • In-transit metastasis of the
    skin (without evidence of
    nodal, parotid, or distant
    disease)
Location of disease
  • Periorbital lesions
    threatening the eye
  • Nasal or auricular lesion
    requiring rhinectomy or
    auriculectomy
  • CSCC lesions of head and
    neck area with direct
    extension into sinuses
Expected deformity or
morbidity
  • Anticipation of substantial
    morbidity or deformity from
    surgery
Recurrence
  • Recurrence of CSCC at the
    same site after 2 or more
    surgical procedures
  • Deep recurrence underlying
    site of previously resected
    cutaneous lesion (if no
    nodal or metastatic
    involvement)
Other
  • Patient refusal of surgery
  • Other conditions deemed to
    be contraindicating for
    surgery

*Assessment by individual physician or surgeon may vary.

Situations when radiation may not be appropriate3,4*
Location of disease
  • Anatomically challenging locations for which radiation therapy
    (RT) would be associated with unacceptable toxicity
Prior treatment
  • Further RT would exceed the threshold of acceptable
    cumulative dose
Other
  • Patient refusal of RT
  • Clinical judgment that tumor would be unlikely to respond to RT
  • Other conditions deemed to be contraindicating for RT

*Assessment by individual physician or surgeon may vary.

Identifying Patients with Advanced Cutaneous
Squamous Cell Carcinoma

Description
Join medical oncologist Dr Ezra Cohen and surgical oncologist Dr Eric Whitman as they discuss how to identify patients with advanced CSCC who are not candidates for curative surgery or curative radiation and should be considered for consultation with a medical oncologist and systemic therapy.
Please click here for full Prescribing Information